Share Price and Basic Stock Data
Last Updated: January 16, 2026, 12:40 pm
| PEG Ratio | -3.90 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aspira Pathlab & Diagnostics Ltd operates in the Hospitals & Medical Services industry, with its stock currently priced at ₹64.1 and a market capitalization of ₹66.0 Cr. The company has experienced fluctuating revenue, with sales reported at ₹19.54 Cr in March 2022, declining to ₹14.46 Cr by March 2023. However, the trailing twelve months (TTM) sales reached ₹24.53 Cr, indicating a recovery trend. Quarterly sales figures show variability; for instance, sales stood at ₹3.71 Cr in September 2022, peaking at ₹4.64 Cr in June 2024, before hitting ₹6.18 Cr in September 2024. This upward trajectory suggests a potential rebound in demand for diagnostic services. Aspira’s operating profit margin (OPM) has also shown volatility, recorded at 27.07% in September 2025, underscoring a significant recovery from negative margins in earlier quarters. The company’s operational performance reflects both the challenges and opportunities present in the healthcare sector, particularly as it seeks to expand its service offerings and geographic reach.
Profitability and Efficiency Metrics
The profitability metrics for Aspira Pathlab & Diagnostics Ltd exhibit a mixed performance. The company reported a net profit of ₹3.41 Cr, translating to a P/E ratio of 19.4, which is indicative of a relatively high valuation compared to the sector average. The return on equity (ROE) stood at an impressive 33.6%, reflecting efficient utilization of shareholders’ funds. However, the operating profit has fluctuated, with margins dipping to -12.31% in June 2023 before rebounding to 27.07% in September 2025. The interest coverage ratio (ICR) was recorded at a robust 11.27x, suggesting strong ability to cover interest expenses, which is favorable for potential investors. Additionally, the cash conversion cycle (CCC) improved to 16.30 days, indicating enhanced efficiency in managing working capital. Despite these strengths, the company must navigate its historical profitability challenges to sustain growth and investor confidence.
Balance Sheet Strength and Financial Ratios
<p.Aspira Pathlab's balance sheet shows a cautious yet improving financial position. The company reported total assets of ₹20.16 Cr as of September 2025, with total liabilities at ₹17.52 Cr, indicating a manageable debt load. Borrowings have decreased to ₹3.13 Cr, which is significantly lower than previous peaks, allowing for better financial flexibility. The reserves stood at ₹4.13 Cr, showcasing a recovery from negative reserves in earlier years. The book value per share, inclusive of revaluation reserves, increased to ₹7.03, reflecting an upward trend in asset valuation. Financial ratios such as the current ratio (2.26) and quick ratio (2.05) indicate strong liquidity, essential for operational stability. However, the price-to-book value (P/BV) of 12.12x suggests the stock may be overvalued compared to its net asset base, warranting caution for potential investors.Shareholding Pattern and Investor Confidence
The shareholding structure of Aspira Pathlab & Diagnostics Ltd reveals a substantial public float, with public shareholders holding 81.61% of the company as of September 2025, while promoters hold 18.39%. This distribution indicates a broad base of retail investor confidence, which can be beneficial for liquidity. The number of shareholders has steadily increased to 1,755, reflecting growing interest in the stock. However, the declining promoter shareholding, from 19.48% in December 2022 to the current level, could raise concerns regarding insider confidence in the company’s future. Notably, institutional investor participation is absent, which may limit the stock’s appeal to larger, institutional investors. This lack of institutional backing can lead to volatility in stock performance, particularly in response to market conditions or company-specific news.
Outlook, Risks, and Final Insight
Aspira Pathlab & Diagnostics Ltd is positioned for potential growth, given its recent revenue recovery and improving profitability metrics. However, several risks are apparent, including reliance on a narrow range of services and historical profitability challenges that could affect future performance. The healthcare sector’s competitive landscape may pose additional challenges as new players enter the market. Furthermore, the company’s high P/BV ratio suggests that investors should exercise caution regarding valuation. If Aspira can successfully leverage its operational efficiencies and expand its service offerings, it may enhance its market position. Conversely, failure to maintain profitability or manage operational costs could hinder growth. Investors should closely monitor quarterly performance and strategic initiatives to assess the company’s trajectory going forward.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.6 Cr. | 136 | 187/120 | 9.31 | 117 | 2.57 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.3 Cr. | 22.2 | 33.8/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.8 Cr. | 10.5 | 20.5/7.08 | 121 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 108 Cr. | 57.7 | 98.7/55.2 | 23.9 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.4 Cr. | 3.60 | 6.94/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,030.64 Cr | 690.98 | 90.24 | 93.18 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.71 | 4.37 | 3.41 | 2.60 | 3.32 | 3.46 | 3.82 | 4.64 | 6.18 | 5.41 | 5.78 | 5.25 | 8.09 |
| Expenses | 3.25 | 3.56 | 3.26 | 2.92 | 3.68 | 3.83 | 3.95 | 4.29 | 4.83 | 4.65 | 4.73 | 4.44 | 5.90 |
| Operating Profit | 0.46 | 0.81 | 0.15 | -0.32 | -0.36 | -0.37 | -0.13 | 0.35 | 1.35 | 0.76 | 1.05 | 0.81 | 2.19 |
| OPM % | 12.40% | 18.54% | 4.40% | -12.31% | -10.84% | -10.69% | -3.40% | 7.54% | 21.84% | 14.05% | 18.17% | 15.43% | 27.07% |
| Other Income | 0.07 | 0.12 | 0.07 | 0.10 | 0.14 | 0.10 | 0.08 | 0.09 | 0.08 | 0.09 | 0.13 | 0.11 | 0.14 |
| Interest | 0.11 | 0.10 | 0.10 | 0.10 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 |
| Depreciation | 0.40 | 0.39 | 0.38 | 0.39 | 0.39 | 0.38 | 0.38 | 0.38 | 0.36 | 0.39 | 0.37 | 0.37 | 0.40 |
| Profit before tax | 0.02 | 0.44 | -0.26 | -0.71 | -0.71 | -0.74 | -0.51 | -0.02 | 0.99 | 0.37 | 0.72 | 0.46 | 1.83 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 0.02 | 0.44 | -0.26 | -0.72 | -0.71 | -0.74 | -0.50 | -0.02 | 0.99 | 0.38 | 0.72 | 0.47 | 1.84 |
| EPS in Rs | 0.02 | 0.43 | -0.25 | -0.70 | -0.69 | -0.72 | -0.49 | -0.02 | 0.96 | 0.37 | 0.70 | 0.46 | 1.79 |
Last Updated: December 28, 2025, 12:16 am
Below is a detailed analysis of the quarterly data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 8.09 Cr.. The value appears strong and on an upward trend. It has increased from 5.25 Cr. (Jun 2025) to 8.09 Cr., marking an increase of 2.84 Cr..
- For Expenses, as of Sep 2025, the value is 5.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.44 Cr. (Jun 2025) to 5.90 Cr., marking an increase of 1.46 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.19 Cr.. The value appears strong and on an upward trend. It has increased from 0.81 Cr. (Jun 2025) to 2.19 Cr., marking an increase of 1.38 Cr..
- For OPM %, as of Sep 2025, the value is 27.07%. The value appears strong and on an upward trend. It has increased from 15.43% (Jun 2025) to 27.07%, marking an increase of 11.64%.
- For Other Income, as of Sep 2025, the value is 0.14 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Jun 2025) to 0.14 Cr., marking an increase of 0.03 Cr..
- For Interest, as of Sep 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Jun 2025) to 0.10 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Sep 2025, the value is 0.40 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.37 Cr. (Jun 2025) to 0.40 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.83 Cr.. The value appears strong and on an upward trend. It has increased from 0.46 Cr. (Jun 2025) to 1.83 Cr., marking an increase of 1.37 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 1.84 Cr.. The value appears strong and on an upward trend. It has increased from 0.47 Cr. (Jun 2025) to 1.84 Cr., marking an increase of 1.37 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.79. The value appears strong and on an upward trend. It has increased from 0.46 (Jun 2025) to 1.79, marking an increase of 1.33.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:09 am
| Metric | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.76 | 4.36 | 7.64 | 8.42 | 15.21 | 19.54 | 14.46 | 13.20 | 22.00 | 24.53 |
| Expenses | 0.02 | 0.14 | 0.23 | 3.34 | 8.24 | 10.88 | 10.25 | 11.69 | 13.16 | 12.86 | 14.38 | 18.44 | 19.72 |
| Operating Profit | -0.02 | -0.14 | -0.23 | -2.58 | -3.88 | -3.24 | -1.83 | 3.52 | 6.38 | 1.60 | -1.18 | 3.56 | 4.81 |
| OPM % | -339.47% | -88.99% | -42.41% | -21.73% | 23.14% | 32.65% | 11.07% | -8.94% | 16.18% | 19.61% | |||
| Other Income | 0.02 | 0.21 | 0.32 | 0.31 | 0.22 | 0.25 | 0.29 | 0.20 | 0.09 | 0.32 | 0.42 | 0.36 | 0.47 |
| Interest | 0.00 | 0.00 | 0.05 | 0.26 | 0.80 | 0.96 | 1.01 | 0.89 | 0.37 | 0.42 | 0.37 | 0.35 | 0.37 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.20 | 1.12 | 1.23 | 1.66 | 1.44 | 1.64 | 1.59 | 1.54 | 1.49 | 1.53 |
| Profit before tax | 0.00 | 0.07 | 0.04 | -2.73 | -5.58 | -5.18 | -4.21 | 1.39 | 4.46 | -0.09 | -2.67 | 2.08 | 3.38 |
| Tax % | 57.14% | 25.00% | 0.00% | 0.00% | 0.00% | 0.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | 0.00 | 0.02 | 0.03 | -2.72 | -5.58 | -5.18 | -4.24 | 1.38 | 4.46 | -0.09 | -2.67 | 2.07 | 3.41 |
| EPS in Rs | 0.00 | 0.09 | 0.13 | -5.24 | -10.75 | -6.32 | -4.56 | 1.34 | 4.33 | -0.09 | -2.59 | 2.01 | 3.32 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | -9166.67% | -105.15% | 7.17% | 18.15% | 132.55% | 223.19% | -102.02% | -2866.67% | 177.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | -9216.67% | 9061.52% | 112.32% | 10.98% | 114.40% | 90.64% | -325.21% | -2764.65% | 3044.19% |
Aspira Pathlab & Diagnostics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 4% |
| TTM: | 48% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 59% |
| 5 Years: | 20% |
| 3 Years: | -23% |
| TTM: | 230% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 13% |
| 1 Year: | 99% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | -3% |
| Last Year: | 24% |
Last Updated: September 5, 2025, 2:26 pm
Balance Sheet
Last Updated: January 7, 2026, 5:01 pm
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 2.25 | 2.25 | 5.19 | 5.19 | 8.19 | 9.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 |
| Reserves | 0.19 | 1.36 | 1.39 | 0.72 | -4.86 | -7.93 | -10.42 | -6.91 | -2.43 | -2.47 | -5.08 | -3.01 | 4.13 |
| Borrowings | -0.00 | -0.00 | 2.62 | 7.29 | 11.36 | 12.52 | 13.80 | 7.01 | 8.85 | 8.24 | 7.71 | 8.13 | 3.13 |
| Other Liabilities | 0.03 | 0.21 | 0.03 | 1.66 | 0.84 | 2.02 | 1.67 | 1.39 | 1.42 | 1.28 | 1.79 | 2.11 | 2.61 |
| Total Liabilities | 0.62 | 3.82 | 6.29 | 14.86 | 12.53 | 14.80 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 | 20.16 |
| Fixed Assets | -0.00 | -0.00 | 0.04 | 7.79 | 7.91 | 8.90 | 8.70 | 7.75 | 9.57 | 8.01 | 6.79 | 6.53 | 6.71 |
| CWIP | -0.00 | -0.00 | -0.00 | 0.25 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.13 | -0.00 |
| Other Assets | 0.62 | 3.82 | 6.25 | 6.82 | 4.62 | 5.90 | 5.64 | 4.03 | 8.56 | 9.33 | 7.92 | 10.86 | 13.45 |
| Total Assets | 0.62 | 3.82 | 6.29 | 14.86 | 12.53 | 14.80 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 | 20.16 |
Below is a detailed analysis of the balance sheet data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.29 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.29 Cr..
- For Reserves, as of Sep 2025, the value is 4.13 Cr.. The value appears strong and on an upward trend. It has increased from -3.01 Cr. (Mar 2025) to 4.13 Cr., marking an increase of 7.14 Cr..
- For Borrowings, as of Sep 2025, the value is 3.13 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8.13 Cr. (Mar 2025) to 3.13 Cr., marking a decrease of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2.61 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.11 Cr. (Mar 2025) to 2.61 Cr., marking an increase of 0.50 Cr..
- For Total Liabilities, as of Sep 2025, the value is 20.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.52 Cr. (Mar 2025) to 20.16 Cr., marking an increase of 2.64 Cr..
- For Fixed Assets, as of Sep 2025, the value is 6.71 Cr.. The value appears strong and on an upward trend. It has increased from 6.53 Cr. (Mar 2025) to 6.71 Cr., marking an increase of 0.18 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.13 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.13 Cr..
- For Other Assets, as of Sep 2025, the value is 13.45 Cr.. The value appears strong and on an upward trend. It has increased from 10.86 Cr. (Mar 2025) to 13.45 Cr., marking an increase of 2.59 Cr..
- For Total Assets, as of Sep 2025, the value is 20.16 Cr.. The value appears strong and on an upward trend. It has increased from 17.52 Cr. (Mar 2025) to 20.16 Cr., marking an increase of 2.64 Cr..
Notably, the Reserves (4.13 Cr.) exceed the Borrowings (3.13 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.02 | -0.14 | -2.85 | -9.87 | -15.24 | -15.76 | -15.63 | -3.49 | -2.47 | -6.64 | -8.89 | -4.57 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43.22 | 29.30 | 38.22 | 26.01 | 40.80 | 83.87 | 59.07 | 61.94 | 38.99 | |||
| Inventory Days | 312.86 | 103.88 | 45.22 | 51.36 | 51.35 | 46.50 | 58.40 | 62.69 | 50.31 | |||
| Days Payable | 730.00 | 64.58 | 46.84 | 73.37 | 91.60 | 70.91 | 51.10 | 101.70 | 73.00 | |||
| Cash Conversion Cycle | -373.92 | 68.61 | 36.60 | 4.00 | 0.55 | 59.46 | 66.37 | 22.93 | 16.30 | |||
| Working Capital Days | -2,199.61 | -5.86 | -96.03 | -127.01 | 16.32 | 69.30 | 48.72 | 25.16 | 14.10 | |||
| ROCE % | 0.00% | 1.82% | -25.39% | -38.41% | -34.49% | -25.15% | 19.77% | 35.65% | 2.01% | -15.87% | 17.37% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.97 | -2.60 |
| Diluted EPS (Rs.) | 1.97 | -2.60 |
| Cash EPS (Rs.) | 3.46 | -1.10 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 7.03 | 5.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 7.03 | 5.07 |
| Revenue From Operations / Share (Rs.) | 21.37 | 12.83 |
| PBDIT / Share (Rs.) | 3.80 | -0.74 |
| PBIT / Share (Rs.) | 2.35 | -2.24 |
| PBT / Share (Rs.) | 2.01 | -2.60 |
| Net Profit / Share (Rs.) | 2.01 | -2.60 |
| NP After MI And SOA / Share (Rs.) | 1.97 | -2.60 |
| PBDIT Margin (%) | 17.79 | -5.79 |
| PBIT Margin (%) | 11.00 | -17.45 |
| PBT Margin (%) | 9.42 | -20.23 |
| Net Profit Margin (%) | 9.42 | -20.23 |
| NP After MI And SOA Margin (%) | 9.19 | -20.23 |
| Return on Networth / Equity (%) | 27.94 | -51.25 |
| Return on Capital Employeed (%) | 16.03 | -18.23 |
| Return On Assets (%) | 11.58 | -18.16 |
| Asset Turnover Ratio (%) | 1.37 | 0.00 |
| Current Ratio (X) | 2.26 | 2.10 |
| Quick Ratio (X) | 2.05 | 1.89 |
| Inventory Turnover Ratio (X) | 45.90 | 0.00 |
| Interest Coverage Ratio (X) | 11.27 | -2.08 |
| Interest Coverage Ratio (Post Tax) (X) | 6.97 | -6.27 |
| Enterprise Value (Cr.) | 86.79 | 31.60 |
| EV / Net Operating Revenue (X) | 3.95 | 2.39 |
| EV / EBITDA (X) | 22.18 | -41.27 |
| MarketCap / Net Operating Revenue (X) | 3.99 | 2.42 |
| Price / BV (X) | 12.12 | 6.12 |
| Price / Net Operating Revenue (X) | 3.99 | 2.42 |
| EarningsYield | 0.02 | -0.08 |
After reviewing the key financial ratios for Aspira Pathlab & Diagnostics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from -2.60 (Mar 24) to 1.97, marking an increase of 4.57.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from -2.60 (Mar 24) to 1.97, marking an increase of 4.57.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.46. This value is within the healthy range. It has increased from -1.10 (Mar 24) to 3.46, marking an increase of 4.56.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 7.03. It has increased from 5.07 (Mar 24) to 7.03, marking an increase of 1.96.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 7.03. It has increased from 5.07 (Mar 24) to 7.03, marking an increase of 1.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 21.37. It has increased from 12.83 (Mar 24) to 21.37, marking an increase of 8.54.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.80. This value is within the healthy range. It has increased from -0.74 (Mar 24) to 3.80, marking an increase of 4.54.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.35. This value is within the healthy range. It has increased from -2.24 (Mar 24) to 2.35, marking an increase of 4.59.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from -2.60 (Mar 24) to 2.01, marking an increase of 4.61.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from -2.60 (Mar 24) to 2.01, marking an increase of 4.61.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 2. It has increased from -2.60 (Mar 24) to 1.97, marking an increase of 4.57.
- For PBDIT Margin (%), as of Mar 25, the value is 17.79. This value is within the healthy range. It has increased from -5.79 (Mar 24) to 17.79, marking an increase of 23.58.
- For PBIT Margin (%), as of Mar 25, the value is 11.00. This value is within the healthy range. It has increased from -17.45 (Mar 24) to 11.00, marking an increase of 28.45.
- For PBT Margin (%), as of Mar 25, the value is 9.42. This value is below the healthy minimum of 10. It has increased from -20.23 (Mar 24) to 9.42, marking an increase of 29.65.
- For Net Profit Margin (%), as of Mar 25, the value is 9.42. This value is within the healthy range. It has increased from -20.23 (Mar 24) to 9.42, marking an increase of 29.65.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.19. This value is within the healthy range. It has increased from -20.23 (Mar 24) to 9.19, marking an increase of 29.42.
- For Return on Networth / Equity (%), as of Mar 25, the value is 27.94. This value is within the healthy range. It has increased from -51.25 (Mar 24) to 27.94, marking an increase of 79.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.03. This value is within the healthy range. It has increased from -18.23 (Mar 24) to 16.03, marking an increase of 34.26.
- For Return On Assets (%), as of Mar 25, the value is 11.58. This value is within the healthy range. It has increased from -18.16 (Mar 24) to 11.58, marking an increase of 29.74.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.37. It has increased from 0.00 (Mar 24) to 1.37, marking an increase of 1.37.
- For Current Ratio (X), as of Mar 25, the value is 2.26. This value is within the healthy range. It has increased from 2.10 (Mar 24) to 2.26, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 2.05. This value exceeds the healthy maximum of 2. It has increased from 1.89 (Mar 24) to 2.05, marking an increase of 0.16.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 45.90. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 45.90, marking an increase of 45.90.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.27. This value is within the healthy range. It has increased from -2.08 (Mar 24) to 11.27, marking an increase of 13.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.97. This value is within the healthy range. It has increased from -6.27 (Mar 24) to 6.97, marking an increase of 13.24.
- For Enterprise Value (Cr.), as of Mar 25, the value is 86.79. It has increased from 31.60 (Mar 24) to 86.79, marking an increase of 55.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 3. It has increased from 2.39 (Mar 24) to 3.95, marking an increase of 1.56.
- For EV / EBITDA (X), as of Mar 25, the value is 22.18. This value exceeds the healthy maximum of 15. It has increased from -41.27 (Mar 24) to 22.18, marking an increase of 63.45.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.99, marking an increase of 1.57.
- For Price / BV (X), as of Mar 25, the value is 12.12. This value exceeds the healthy maximum of 3. It has increased from 6.12 (Mar 24) to 12.12, marking an increase of 6.00.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.99, marking an increase of 1.57.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.08 (Mar 24) to 0.02, marking an increase of 0.10.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aspira Pathlab & Diagnostics Ltd:
- Net Profit Margin: 9.42%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.03% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 27.94% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.2 (Industry average Stock P/E: 90.24)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.42%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Flat No.2, R.D. Shah Building, Mumbai Maharashtra 400086 | info@aspiradiagnostics.com http://www.aspiradiagnostics.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Haseeb A Drabu | Chairman & Ind.Director |
| Dr. Pankaj J Shah | Managing Director & CEO |
| Mr. Nikunj V Mange | Executive Director |
| Mrs. Mangala R Prabhu | Independent Director |
| Dr. Manas R Mengar | Independent Director |
FAQ
What is the intrinsic value of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd's intrinsic value (as of 17 January 2026) is ₹73.53 which is 9.75% higher the current market price of ₹67.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹69.0 Cr. market cap, FY2025-2026 high/low of ₹107/50.5, reserves of ₹4.13 Cr, and liabilities of ₹20.16 Cr.
What is the Market Cap of Aspira Pathlab & Diagnostics Ltd?
The Market Cap of Aspira Pathlab & Diagnostics Ltd is 69.0 Cr..
What is the current Stock Price of Aspira Pathlab & Diagnostics Ltd as on 17 January 2026?
The current stock price of Aspira Pathlab & Diagnostics Ltd as on 17 January 2026 is ₹67.0.
What is the High / Low of Aspira Pathlab & Diagnostics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aspira Pathlab & Diagnostics Ltd stocks is ₹107/50.5.
What is the Stock P/E of Aspira Pathlab & Diagnostics Ltd?
The Stock P/E of Aspira Pathlab & Diagnostics Ltd is 20.2.
What is the Book Value of Aspira Pathlab & Diagnostics Ltd?
The Book Value of Aspira Pathlab & Diagnostics Ltd is 14.0.
What is the Dividend Yield of Aspira Pathlab & Diagnostics Ltd?
The Dividend Yield of Aspira Pathlab & Diagnostics Ltd is 0.00 %.
What is the ROCE of Aspira Pathlab & Diagnostics Ltd?
The ROCE of Aspira Pathlab & Diagnostics Ltd is 17.4 %.
What is the ROE of Aspira Pathlab & Diagnostics Ltd?
The ROE of Aspira Pathlab & Diagnostics Ltd is 33.6 %.
What is the Face Value of Aspira Pathlab & Diagnostics Ltd?
The Face Value of Aspira Pathlab & Diagnostics Ltd is 10.0.